Company Filing History:

16 out of 3,840

Imperial Chemical Industries Limited

patents

4 out of 1,200

National Research Development Corporation

patents

where one patent can have more than one assignee

Years Active: 1983-1995

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5395838 - 6-substituted quinazolines processing anti-tumor activity (1995-03-07),

2. 5252573 - Anti-tumor agents (1993-10-12),

3. 5236953 - Alkene, alkyne or cycloalkylene derivatives (1993-08-17),

4. 5187167 - Pharmaceutical compositions comprising quinazolin-4-one derivatives (1993-02-16),

5. 5112837 - Quinoline derivatives having anti-tumor activity (1992-05-12),

6. 5089499 - Quinazoline derivatives possessing anti-tumor activity (1992-02-18),

7. 5084478 - Alkene, alkyne or cycloalkylene derivatives (1992-01-28),

8. 5081124 - Method of producing antitumor effect using quinazolin-4-one derivatives (1992-01-14),

9. 5032592 - Alkene, alkyne or cycloalkylene derivatives (1991-07-16),

10. 4992550 - Anti-tumour agents (1991-02-12),

11. 4985441 - Anti-tumor agents (1991-01-15),

12. 4981856 - Anti-tumor agents (1991-01-01),

13. 4873329 - Alkene, alkyne or cycloalkylene derivatives (1989-10-10),

14. 4845119 - Alkene, alkyne or cycloalkylene derivatives (1989-07-04),

15. 4535092 - Acylanilides having antiandrogenic activity (1985-08-13),

Title: **Leslie R Hughes: Innovator in Anti-Tumor Pharmaceuticals**

Introduction

Leslie R Hughes, based in Macclesfield, GB, has made significant contributions to the field of pharmaceuticals, particularly in the development of quinazoline derivatives with anti-tumor properties. With an impressive portfolio of 16 patents, Hughes stands out as a prominent inventor focused on addressing critical health issues through innovative solutions.

Latest Patents

Two of Leslie R Hughes' latest patents focus on 6-substituted quinazolines, which exhibit notable anti-tumor activity. These inventions detail the processes for manufacturing quinazoline derivatives or their pharmaceutically-acceptable salts. The formulations provided offer a quinazoline of the formula: R1, where R1 can be hydrogen, amino, alkyl, or alkoxy groups with up to six carbon atoms, as well as substituted alkyl or alkoxy groups with up to three carbon atoms. This remarkable innovation highlights her commitment to advancing medical science through effective treatments for cancer.

Career Highlights

Leslie R Hughes has been associated with prominent organizations during her career, including Imperial Chemical Industries Limited and the National Research Development Corporation. These experiences have significantly shaped her expertise and contributed to her successful patent applications, culminating in advanced pharmaceutical research.

Collaborations

Throughout her career, Hughes has worked alongside notable colleagues such as John Oldfield and Howard Tucker. These collaborations have not only fostered innovation but also strengthened her contributions to the field of pharmaceutical sciences.

Conclusion

Leslie R Hughes continues to be a leading figure in the inventive landscape of anti-tumor pharmaceuticals, with her patents laying the groundwork for future advancements in cancer treatment. Through her dedication to research and collaboration, she is poised to make a lasting impact on medical innovation and patient care.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com